Intercellular adhesion molecule 1 (ICAM-1) is a member of the immunoglobulin superfamily that interacts with two integrins, LFA-1 and Mac-1. These interactions are critical for leukocyte extravasation into inflamed tissue. To assess the role of ICAM-1 expression in the pathogenesis of bacterial infection, homozygously mutant mice lacking the ICAM-1 gene were exposed to Staphylococcus aureus. Within 6 days after inoculation 50% of the animals in the ICAM-1 ؊/؊ group, but none of the controls, had died. Despite the high level of mortality, ICAM-1 ؊/؊ mice developed less frequent and less severe arthritis than their wild-type littermates. In agreement, normal mice inoculated with staphylococci and administered anti-ICAM-1 antibodies exhibited a higher frequency of mortality but less severe arthritis than the controls. Our results indicate that ICAM-1 on the one hand provides protection against systemic disease but on the other hand aggravates the local disease manifestation.
Intercellular adhesion molecule 1 (ICAM-1) is an integral membrane protein that is a member of the immunoglobulin superfamily (12) . ICAM-1 plays an important role in cell adhesion and migration, as well as in immune responses. Under normal conditions, the level of ICAM-1 expression is quite low, but it is upregulated during inflammation by a variety of cytokines, such as interleukin-1␤ (IL-1␤), tumor necrosis factor alpha (TNF-␣), and gamma interferon (IFN-␥) (13) . The counterreceptors for ICAM-1 are the ␤ 2 integrins LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18). We have recently established a superantigen-enhanced and T-cell-mediated (1, 2, 5) model of Staphylococcus aureus septicemia and arthritis in which a single intravenous inoculation of the toxic shock syndrome toxin 1 (TSST-1)-producing S. aureus strain LS-1 within days leads to a rapid deterioration of joints (3, 9) . One of the hallmarks of the disease is a rapid extravasation of phagocytic cells and T lymphocytes into the synovial tissue (5, 8) , which in S. aureus-infected mice contains a plethora of activated and clonally expanded V␤11 ϩ CD4 ϩ cells. These cells produce large amounts of IFN-␥, an arthritogenic cytokine (22) . The aim of this study was to assess the role of ICAM-1 expression in the pathogenesis of S. aureus septicemia and arthritis. Homozygous female ICAM-1 mutant (ICAM-1
Ϫ/Ϫ
) and wild-type (ICAM-1 ϩ/ϩ ) mice were obtained as previously described (20) . Swiss mice were used in the monoclonal antibody depletion experiments. Hybridoma cell line YN1/1.7.4, obtained from the American Type Culture Collection (Rockville, Md.), produces a rat immunoglobulin G2b (IgG2b) antibody specific for mouse ICAM-1. A rat IgG2a antibody specific for ovalbumin was used as a control antibody.
S. aureus LS-1 was originally isolated from a swollen joint of a spontaneously arthritic NZB/W mouse (7) .
Twelve mice deficient in ICAM-1 and 12 wild-type littermates were injected intravenously with an amount of S. aureus corresponding to 4 ϫ 10 6 CFU per mouse. They were sacrificed on day 6 after inoculation of bacteria.
In another experiment, 45 Swiss mice were given 2 ϫ 10 7 CFU of an S. aureus suspension. Three days after the inoculation, 25 mice were injected intraperitoneally with 0.2 mg of anti-ICAM-1 antibody (YN1/1.7.4.), and 20 mice were injected with 0.2 mg of control rat IgG. The antibodies were administered three times per week until sacrifice 14 days later. Arthritis was defined as visible joint swelling and/or erythema of at least one joint. A clinical evaluation of arthritis was carried out with a system in which macroscopic evaluation of arthritis yields a score of 0 to 3 for each paw. An arthritic index was constructed by the addition of scores for all four paws in each mouse (1) .
Histopathological sections of the joints were evaluated with regard to synovial hypertrophy, pannus formation, and cartilage and subchondral bone destruction. The phagocytic activities of circulating monocytes and granulocytes in healthy ICAM-1-deficient and wild-type congenic mice were determined by incubation of fluorescein isothiocyanate-labeled bacteria (Orpegen Pharma, Heidelberg, Germany), and the fluorescence was recorded with a FACScan (Becton-Dickinson, Mountain View, Calif.). Leukocyte counts were determined in a hemacytometer (Toa Medical Electronics, Kobe, Japan). Splenic mononuclear cells from healthy mutant and wild-type mice were isolated and suspended at a concentration of 10 6 /ml in 24-well culture dishes in Iscove's medium (Gibco, Paisley, United Kingdom) supplemented with 10% heat-inactivated fe-tal calf serum, L-glutamine, mercaptoethanol, and gentamicin. The cell suspensions were incubated with 2.5 g of concanavalin A (ConA) per ml, 10 g of TSST-1 (Toxin Technology, Madison, Wis.) per ml, or 10 7 CFU of formalin-killed S. aureus LS-1 per ml. The proliferation assay was performed in 96-well microtiter plates, with culture for 72 h. During the last 12 h, 1 Ci of [ 3 H]thymidine per well was added. The analysis of levels of IFN-␥, TNF-␣ and IL-6 in sera and supernatants was performed by enzyme-linked immunosorbent assay or bioassay as previously described (21, 23) . Levels of total immunoglobulin, IgG1, IgG2a, IgG2b, IgG3, and IgM in serum were measured by the single radial immunodiffusion technique (16) .
Statistical analysis of the differences between means was carried out with Student's two-tailed t test. The chi-square test was used to analyze categorical data. P values of below 0.05 are regarded as significant.
Intravenous inoculation of ICAM-1-deficient mice with S. aureus resulted in a high level of mortality. At the termination of the experiment, 6 days after the bacterial inoculation, 6 of 12 ICAM-1-deficient mice were dead. With a single exception, the remaining animals did not develop arthritis. In the wild-type group, all 12 animals stayed alive (Fig. 1) . However, the animals in the wild-type group developed a more prevalent and more severe arthritis than the mutants (Fig. 2) . Two days after bacterial injection, 6 of 12 wild-type mice but only 1 of 12 ICAM-1 mutant mice displayed clinical signs of arthritis. Four days later, at the time of sacrifice, 5 of 12 in the wild-type group and 1 of 6 in the ICAM-1-deficient group showed clinical arthritis ( Fig. 2A) . When the joints were analyzed for histopathological signs of arthritis, the mice in the ICAM-1 mutant group exhibited less destruction of joint cartilage and bone (33 versus 45%) and less hypertrophy of synovial tissue (50 versus 82%) than the wild-type littermates. In addition, three mice from the wild-type group but none from the ICAM-1
group displayed osteitis and extra-articular granulomas. The histopathological findings are thus in agreement with the clinical findings, where the wild-type mice were found to have signs of a more severe arthritis.
No significant differences were found between the wild-type and the mutant groups with respect to bacterial growth in the spleen, kidneys, blood, or joints (data not shown). Table 1 shows levels of cytokines and immunoglobulins in serum during S. aureus infection in ICAM-1-deficient mice and wild-type littermates. There were no significant differences with respect to levels of circulating IFN-␥ or IL-6 between the two groups. In contrast, ICAM-1-deficient mice displayed significantly higher levels of IgG2a (P Ͻ 0.05) and IgM (P Ͻ 0.05). groups of mice (data not shown). In contrast, ICAM-1 ϩ/ϩ mice displayed lower in vitro production of TNF-␣ in response to ConA (53 Ϯ 16 versus 130 Ϯ 57 pg/ml), S. aureus (63 Ϯ 13 versus 80 Ϯ 16 pg/ml), and TSST-1 (66 Ϯ 15 versus 126 Ϯ 23 pg/ml) (P Ͻ 0.05) than did ICAM-1 Ϫ/Ϫ mice. There were no significant differences with respect to the secretion of IL-6 when spleen cells from the mutant and wildtype groups were stimulated with ConA, TSST-1, or S. aureus cell walls. The number of circulating neutrophils was significantly higher in ICAM-1 mutants than in the wild-type congenic mice, as previously reported (1,130 ϫ 10 9 Ϯ 182 ϫ 10 9 /liter versus 404 ϫ 10 9 Ϯ 98 ϫ 10 9 /liter; P Ͻ 0.01) (20) . However, the ICAM-1-deficient mice proved to have a significantly lower proportion of phagocytizing cells than their wildtype littermates (17.7% Ϯ 1.2% versus 25.3% Ϯ 2.0%; P Ͻ 0.01).
Consistent with the results from the experiment with ICAM-1-deficient mice, there was a tendency for a higher level of mortality in the group of animals treated with anti-ICAM-1 antibody. Four days after bacterial inoculation, 5 of 25 mice died, but only 1 of 20 mice in the control group died. By the time the experiment was terminated on day 14 after inoculation of bacteria, 72% in the anti-ICAM-1-treated group and 40% in the control group had died. The frequency of septic arthritis in mice treated with anti-ICAM-1 antibody was lower than that in rat IgG-treated controls during the first week of S. aureus infection. Thus, on day 4 after bacterial administration, the anti-ICAM-1-treated animals displayed a significantly lower frequency of arthritis than the controls (15 versus 68%; P Ͻ 0.01). The severity of arthritis parallelled this observation; the arthritic index decreased in the anti-ICAM-1-treated animals from 0.6 Ϯ 0.1 on day 2 to 0.35 Ϯ 0.2 on day 4 after the bacterial inoculation. In contrast, control mice displayed an increased arthritic index, from 0.5 Ϯ 0.1 to 1.1 Ϯ 0.2, during the corresponding period (P Ͻ 0.01 with regard to arthritic index at day 4 between anti-ICAM-1-treated mice and controls).
Mice genetically and functionally deficient in ICAM-1 exhibit greater mortality but less-destructive arthritis than their wild-type littermates during S. aureus infection. At the time of sacrifice, 50% of the animals in the ICAM-1 mutant group were dead and the remaining were in poor condition, while all of the mice in the wild-type group were alive and in good condition. By contrast, in a previous study we found that ICAM-1 Ϫ/Ϫ mice are more resistant to S. aureus enterotoxin B-induced septic shock than ICAM-1 ϩ/ϩ controls (20) . The present study highlights the difference between infection with a superantigen-producing bacterium and exposure of healthy animals to superantigen alone. Despite septicemia-induced death, ICAM-1 mutants showed only sparse clinical and histological signs of arthritis. Similar findings regarding the clinical development of septic death and arthritis were obtained in an independent experiment using in vivo administration of anti-ICAM-1. What are the reasons for the highly discrepant outcomes regarding septic mortality and septic arthritis in ICAM-1 deficiency? One of the key events in all localized inflammatory conditions (e.g., septic arthritis) is extravasation of inflammatory cells. In this respect, the interactions between ICAM-1 and LFA-1/Mac-1 are critical for leukocyte migration and adhesion. Our results showing that ICAM-1 deficiency decreases the severity of arthritis are supported by recent studies on rheumatoid arthritis (11, 18) and on animal models of autoimmune arthritis (14, 15, 17) . Apart from its importance for extravasation, the ICAM-1 molecule is also involved in the interaction between T lymphocytes and antigen-presenting cells (10, 13) . Given that S. aureus arthritis is a T-cell-mediated disease (2, 5) , deficient expression of ICAM-1 should reduce the antigen-presenting capacity and hence contribute to a less destructive course of the disease. In striking contrast to the case for arthritis, the same S. aureus-inoculated animals with either genomic or phenotypic ICAM-1 deficiency developed severe systemic manifestations such as sepsis, which frequently led to death. The main participants in the host defense system against staphylococcal infections are phagocytic, CD43-expressing cells (6) , whereas T and B lymphocytes aggravate the systemic manifestations of the disease (4, 21) . In this respect it should be noted that despite the presence of high numbers of circulating polymorphonuclear cells, the percentage of cells able to phagocytize bacteria was significantly lower in ICAM-1-deficient mice than in wild-type congenic mice. The nonphagocytized, circulating bacteria and, more importantly, their exotoxins, such as TSST-1, may be potent inducers of TNF-␣, a cytokine mediating lethality in septic shock. Indeed, whereas we could not detect circulating TNF-␣, the in vitro results clearly show that TNF-␣ production in response to TSST-1 is significantly increased in ICAM-1-deficient animals in comparison with wild-type congenic animals. IFN-␥ is produced by antigen-, superantigen-, or mitogen-activated T lymphocytes. It enhances phagocytic functions (19) and increases major histocompatibility complex expression. In our study ICAM-1-deficient mice displayed lower levels of circulating IFN-␥ than the controls. Further in vitro analysis demonstrated that lymphocytes from ICAM-1 Ϫ/Ϫ mice have a decreased capacity to produce IFN-␥ in response to staphylococcal antigens. It is thus plausible that an insufficient IFN-␥ response to staphylococcal infection might have resulted in decreased phagocytic capacity leading to deficient bacterial elimination in ICAM-1 Ϫ/Ϫ mice. Together our results point to a dual role of ICAM-1 expression during S. aureus infection. Whereas ICAM-1 is a critical participant in the host defense against systemic, extracellular bacterial infections, its absence or downregulation may be protective in septic arthritis.
